Introduction
B. Olaisen, Elly Herbschleb-Voogt, L.M.M. Wijnen, T.M. Dijksman, M.P. Cowmeadow, M.A. Ferguson‐Smith(Australian Research Council), P.L. Pearson, A. Estop, W.R.T. Los, P.J.L. Cook, John D. Minna(Center for Neuro-Oncology), F.H. Ruddle, J.L. Hamerton, U. Francke, R. Saisson, Arvid Heiberg(Oslo University Hospital), U. Francke, Jeanne E. Anderson, Hiroko Kaita, Lynda J. Donald, A. Westerveld, M. Bobrow, E.R. Giblett(Public Health – Seattle & King County), H. M. Vriesendorp, P. Meera Khan(Leiden University Medical Center), D.A. Aitken, W.S. Volkers, B.A. Doppert, D. S. Borgaonkar, Karin D. Berg, M. Lewis, E.B. Robson, P. Pearson, J.E. Gray, Marry M. van den Heuvel, P.A. Lalley(Oak Ridge National Laboratory), J.J. Garver, Richard M. Denney
Cited by 7
Related Papers
Age and acute myeloid leukemia
|Blood|2006|1.4k
High-throughput oncogene mutation profiling in human cancer
|Nature Genetics|2007|996
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
|Cancer Cell|2021|930
A pan-cancer proteomic perspective on The Cancer Genome Atlas
|Nature Communications|2014|641